0703 GMT - AstraZeneca's 2030 revenue target looks compelling and the U.K. drugmaker can achieve it through organic growth, J.P. Morgan analysts say in a research note. The Financial Times reported that AstraZeneca held merger talks with U.S. rival Bristol Myers Squibb. AstraZeneca declined to comment, while BMS didn't immediately respond to a request for comment. "We see these unconfirmed reports as surprising as we remain confident in Astra's ability to achieve their 2030 $80 billion revenue target organically and see sufficient depth in the pipeline to sustain growth beyond 2030," the JPM analysts say.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.